Log in

Relevant bibliographies by topics / Cholinesterase; Alzheimer's disease

Contents

Dissertations / Theses

Academic literature on the topic 'Cholinesterase; Alzheimer's disease'

Author: Grafiati

Published: 4 June 2021

Last updated: 15 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cholinesterase; Alzheimer's disease.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Dissertations / Theses on the topic "Cholinesterase; Alzheimer's disease"

1

Giles, Kurt. "Post-translational modifications of acetylcholinesterase." Thesis, University of Oxford, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.260127.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Yau, Kenneth Kwok-Chi. "Assessing and predicting treatment responses to cholinesterase inhibitor pharmacotherapy in Alzheimer's disease." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2000. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape4/PQDD_0015/MQ54172.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Connelly, Stephen. "Studies on pyroglutamyl carboxyl peptidase enzymes and cholinesterase inhibitors : implications for Alzheimer's disease." Thesis, University of Exeter, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.430098.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Spowart-Manning, Laura. "The evaluation of behavioural tasks and animal models of Alzheimer's disease for assessing putative cognition enhancers, using a cholinesterase inhibitor as reference compound." Thesis, University of Bristol, 2001. http://hdl.handle.net/1983/09e768fe-f64c-47c0-b4d4-d0a19b8ff23d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Foka, Germaine Boulenoue. "Synthesis and evaluation of novel coumarin-donepezil derivatives as dual acting monoamine oxidase B and cholinesterase in Alzheimer's disease." University of the Western Cape, 2016. http://hdl.handle.net/11394/5549.

Full text

Abstract:

Magister Pharmaceuticae - MPharm<br>Alzheimer's disease is a progressive neurodegenerative disease characterised by low acetylcholine (ACh) levels in the hippocampus and cortex of the brain, causing symptoms like progressive memory loss, decline in language skills and other cognitive impairments to occur. The hallmarks of AD include the presence of extracellular insoluble amyloid beta plaques, intracellular neurofibrillary tangles, and the decrease in ACh concentration. The pathophysiology of AD is not well understood, however, acetylcholinesterase (AChE), butyrylcholinesterase (BuChE) and mon

APA, Harvard, Vancouver, ISO, and other styles

6

Svensson, Anne-Lie. "Cholinesterase inhibitors in Alzheimer's disease : an experimental study on mechanisms of interaction with muscarinic and nicotinic receptors and neuroprotection /." Stockholm, 1997. http://diss.kib.ki.se/1997/91-628-2733-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Anderholm, Louise. "Behandling av beteendemässiga ochpsykiska symtom med fokus påagitation hos äldre med Alzheimerssjukdom. : En jämförelse mellan neuroleptika ochacetylkolinesterashämmare." Thesis, Umeå universitet, Farmakologi, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-119733.

Full text

Abstract:

Inledning: År 2030 uppskattas det vara ungefär 230 000 stycken människor i Sverige somhar drabbats av någon typ av demenssjukdom. Sjukdomens stadier delas in i begynnande,mild, måttlig och svår demens. Där första symtomen i den begynnande fasen brukar vara attden drabbade inte kommer ihåg vart den lagt sina saker. I den svåra fasen av sjukdomen ärpatienten förmodligen beroende av dygnet runt vård, patienten brukar även ha svårt attprata, enstaka ord eller meningar brukar upprepas. Beteendemässiga och psykiska symtom(BPSD) hos demenssjuka är symtom som kan orsaka lidande hos patienten och dessa

APA, Harvard, Vancouver, ISO, and other styles

8

Forsström, Karin. "Longitudinal Changes in Astroglial and Inflammatory Markers in Patients with MCI and AD." Thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2011. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-192975.

Full text

Abstract:

Since neuroinflammation is present in patients with mild cognitive impairment (MCI) andAlzheimer's disease (AD) and since cholinesterase inhibitors increases the level ofacetylcholine, the aim was to investigate whether inflammatory markers of cholinoceptive cellsare affected in these patients. Near a biological hallmark of AD, amyloid plaque, activatedastrocytes and microglia can be found and higher levels of proinflammatory cytokines, i.e. IL-1β. To study the inflammatory response, proteins GFAP and S100B are used as CSF glialmarkers. IL-1β can bind to the membrane-bound IL-1 receptor or sol

APA, Harvard, Vancouver, ISO, and other styles

9

Navaratnam, Dasakumar Selveraj. "Cholinesterases in Alzheimer's disease." Thesis, University of Oxford, 1990. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.306734.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Blanco, Silvente Lídia. "La relación beneficio-riesgo del tratamiento farmacológico para la enfermedad de Alzheimer." Doctoral thesis, Universitat de Girona, 2019. http://hdl.handle.net/10803/667938.

Full text

Abstract:

The evidence available in the medical literature is conclusive that the risk-benefit relationship of the current medications for Alzheimer's disease is not favourable. This risk-benefit relationship is not significantly modified by any factor related to the design of the clinical trials, neither with the intervention nor with patient’s characteristics. It is also important to highlight that redundant studies that do not provide new evidence have been identified, so the realization of new clinical trials to evaluate the efficacy and safety of current medications for Alzheimer's disease would be

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!